Response Evaluation Criteria and Performance Scales

Article

In clinical studies, formal response criteria have been developed and have gained wide acceptance. The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST). In contrast, the World Health Organization (WHO) has a different standard for assessing response. Major differences between these guidelines are outlined below.

Recist: Definition of Response

In clinical studies, formal response criteria have been developed and have gained wide acceptance.

The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST).

In contrast, the World Health Organization (WHO) has a different standard for assessing response.

Major differences between these guidelines are outlined below.

Comparison of RECIST and WHO guidelines

Performance Scales

The Karnofsky performance index and WHO (Zubrod) scale are commonly used as proxy measures for quality of life.

Because they measure only one dimension of the construct, they would not be considered quality-of-life measures by today’s standards.

However, given their historic relevance and current high frequency of usage as proxy measures, we have included them here.

Karnofsky performance index and WHO (Zubrod) scale

Recent Videos
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content